目的 探讨心肌泰胶囊联合注射用环磷腺苷葡胺治疗病毒性心肌炎的临床疗效。方法 选取2022年7月—2025年6月在郑州人民医院就诊的病毒性心肌炎患者，共计98例。患者以随机数字表法分为对照组和治疗组，每组49例。对照组滴注注射用环磷腺苷葡胺，120 mg加入300 mL葡萄糖注射液，1次/d。治疗组患者在对照组治疗的基础上口服心肌泰胶囊，5粒/次，3次/d。两组患者均连续治疗4周。比较两组的治疗效果、症状消失时间、心脏彩超检查、血清指标。结果 对照组总有效率为79.59%，治疗组总有效率为93.88%，组间差异显著（P＜0.05）。治疗组患者头晕、心悸、皮肤湿冷、心音低钝消失时间均明显短于对照组（P＜0.05）。两组治疗后的左心室射血分数（EF）明显升高，E/A、Tei指数明显降低（P＜0.05）；治疗组治疗后的左心室EF高于对照组，E/A、Tei指数低于对照组（P＜0.05）。两组治疗后的血清乳酸脱氢酶（LDH）、正五聚蛋白3（PTX-3）、白细胞介素-18（IL-18）、N末端脑钠肽前体（NT-proBNP）水平显著降低（P＜0.05），治疗组治疗后血清LDH、PTX-3、IL-18、NT-proBNP水平低于对照组（P＜0.05）。结论 心肌泰胶囊联合注射用环磷腺苷葡胺可提高病毒性心肌炎的疗效，改善临床症状和心功能，减轻心肌损伤。

Objective To investigate the clinical efficacy of Xinjitai Capsules combined with Meglumine Adenosine Cyclophosphate for injection in treatment of viral myocarditis. Methods A total of 98 patients with viral myocarditis who received treatment at Zhengzhou People’s Hospital from July 2022 to June 2025 were selected. According to the random number table method, patients were divided into control group and treatment group, with 49 cases in each group. The control group received iv infusion of Meglumine Adenosine Cyclophosphate for injection, 120 mg added to 300 mL glucose injection, once daily. The treatment group received oral administration of Xinjitai Capsules on the base of treatment in the control group, 5 capsules/time, 3 times daily. Two groups were treated continuously for 4 weeks. The treatment efficacy, symptom disappearance time, cardiac ultrasound examination, and serum indicators were compared between two groups. Results The total effective rate of the control group was 79.59%, while the total effective rate of the treatment group was 93.88%, with significant differences between the groups (P < 0.05). The disappearance times of dizziness, palpitations, damp and cold skin, and dull heart sounds in the treatment group was significantly shorter than that in the control group (P < 0.05). After treatment, the left ventricular ejection fraction (EF) significantly increased in two groups, while the E/A and Tei indices significantly decreased (P < 0.05). The left ventricular EF of the treatment group was higher than that of the control group after treatment, while the E/A and Tei indices were lower than those of the control group (P < 0.05). After treatment, the serum levels of lactate dehydrogenase (LDH), pentameric protein 3 (PTX-3), interleukin-18 (IL-18), and N-terminal pro brain natriuretic peptide (NT-proBNP) in two groups were significantly reduced (P < 0.05). The serum levels of LDH, PTX-3, IL-18, and NT-proBNP in the treatment group were lower than those in the control group after treatment (P < 0.05). Conclusion The combination of Xinjitai Capsules and Meglumine Adenosine Cyclophosphate for injection can improve the efficacy of viral myocarditis, improve clinical symptoms and heart function, and alleviate myocardial injury.

R972

河南省医学科技公关项目（LHGJ20210697）